# GAGE1

## Overview
GAGE1 is a gene that encodes the G antigen 1 protein, a member of the GAGE family of cancer/testis antigens. These proteins are characterized by their intrinsic disorder, lacking stable secondary or tertiary structures under physiological conditions, which allows them to participate in diverse protein-protein interactions (Gjerstorff2012GAGE; Rajagopalan2011A). G antigen 1 is notable for its ability to bind double-stranded DNA in a sequence-independent manner, suggesting a role in chromatin organization and regulation (Gjerstorff2012GAGE). The expression of GAGE1 is typically restricted to germ cells in normal tissues but is aberrantly upregulated in various cancers, including breast and ovarian cancer, making it a potential target for cancer immunotherapy (GhafouriFard2014Cancer–Testis; Vlasenkova2023Characterization). The protein's structural flexibility and interaction with nuclear envelope proteins further implicate it in chromatin regulation and tumorigenesis (Gjerstorff2012GAGE).

## Structure
GAGE1 is a member of the GAGE family of proteins, which are characterized by their intrinsic disorder, meaning they lack a stable secondary or tertiary structure under physiological conditions (Gjerstorff2012GAGE; Rajagopalan2011A). The primary structure of GAGE1 includes an unusual amino acid composition with few hydrophobic residues and many charged residues, typical of intrinsically disordered proteins (IDPs) (Gjerstorff2012GAGE). While most GAGE proteins lack distinct secondary structures, GAGE1 is noted to have a unique C-terminal domain that is predicted to be alpha-helical, indicating some secondary structure (Gjerstorff2012GAGE).

GAGE proteins, including GAGE1, are capable of forming stable dimers and higher-order oligomers, suggesting some level of quaternary structure (Gjerstorff2012GAGE). They can bind double-stranded DNA in a sequence-independent manner, which may involve oligomerization at high concentrations (Gjerstorff2012GAGE). Post-translational modifications such as phosphorylation and acetylation are common in cancer/testis antigens like GAGE1, potentially influencing their interactions and functions (Rajagopalan2011A). The structural flexibility of GAGE1 allows it to engage in various protein-protein interactions, which may be relevant to its role in cancer (Rajagopalan2011A).

## Clinical Significance
GAGE1, a member of the GAGE gene family, is associated with various cancers, including breast and ovarian cancer. Its expression is typically restricted to germ cells in healthy tissues but is aberrantly upregulated in several tumor types, making it a potential target for cancer immunotherapy (GhafouriFard2014Cancer–Testis; Vlasenkova2023Characterization). In breast cancer, GAGE1 expression is notably higher in estrogen receptor-negative tumors and is detected in nuclear, cytoplasmic, and nucleolar patterns in infiltrating ductal breast carcinoma (GhafouriFard2014Cancer–Testis). 

In ovarian cancer, GAGE1 is part of a group of cancer/testis antigens that have been studied for their potential as prognostic markers. The expression levels of GAGE1 in ovarian cancer samples suggest its involvement in tumor progression and its potential utility in predicting patient outcomes (Vlasenkova2023Characterization). 

The GAGE gene family, including GAGE1, is also implicated in medullary breast cancer, where it is significantly upregulated compared to ductal breast cancer and normal breast epithelia. This differential expression may contribute to the unique biological features of medullary breast cancer (Gjerstorff2006Identification).

## Interactions
GAGE1, a member of the GAGE family of proteins, is known for its interactions with nucleic acids and other proteins, particularly in the context of cancer and germ cells. GAGE proteins, including GAGE1, are intrinsically disordered and can bind double-stranded DNA (dsDNA) directly, similar to High Mobility Group (HMG) domain proteins. This binding is sequence-independent and occurs at physiological concentrations, suggesting a potential role in chromatin organization and function (Gjerstorff2012GAGE).

GAGE proteins are recruited to the nuclear envelope by the germ cell-less (GCL) protein, a transcriptional regulator that binds LEM-domain proteins at the nuclear envelope. This interaction involves GCL residues 209-320, which include the BACK domain, and suggests that GAGE proteins might compete with other proteins, such as the DP subunit of the E2F-DP transcription factor, for binding to GCL (Gjerstorff2012GAGE).

The dual association of GAGE proteins with GCL at the nuclear envelope and with dsDNA implicates them in chromatin regulation in both germ and cancer cells. This interaction may influence nuclear lamina organization and contribute to tumorigenesis by affecting apoptotic regulators like IRF1 and NPM1 (Gjerstorff2012GAGE).


## References


[1. (Gjerstorff2012GAGE) Morten F. Gjerstorff, Heike I. Rösner, Christina B. Pedersen, Katrine B. V. Greve, Steffen Schmidt, Katherine L. Wilson, Jan Mollenhauer, Hüseyin Besir, Flemming M. Poulsen, Niels Erik Møllegaard, and Henrik J. Ditzel. Gage cancer-germline antigens are recruited to the nuclear envelope by germ cell-less (gcl). PLoS ONE, 7(9):e45819, September 2012. URL: http://dx.doi.org/10.1371/journal.pone.0045819, doi:10.1371/journal.pone.0045819. This article has 15 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0045819)

[2. (Vlasenkova2023Characterization) Ramilia Vlasenkova, Daliya Konysheva, Alsina Nurgalieva, and Ramziya Kiyamova. Characterization of cancer/testis antigens as prognostic markers of ovarian cancer. Diagnostics, 13(19):3092, September 2023. URL: http://dx.doi.org/10.3390/diagnostics13193092, doi:10.3390/diagnostics13193092. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/diagnostics13193092)

[3. (Rajagopalan2011A) Krithika Rajagopalan, Steven M. Mooney, Nehal Parekh, Robert H. Getzenberg, and Prakash Kulkarni. A majority of the cancer/testis antigens are intrinsically disordered proteins. Journal of Cellular Biochemistry, 112(11):3256–3267, October 2011. URL: http://dx.doi.org/10.1002/jcb.23252, doi:10.1002/jcb.23252. This article has 150 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/jcb.23252)

[4. (GhafouriFard2014Cancer–Testis) Soudeh Ghafouri-Fard, Roshanak Shamsi, Mahnaz Seifi-Alan, Mona Javaheri, and Sanaz Tabarestani. Cancer–testis genes as candidates for immunotherapy in breast cancer. Immunotherapy, 6(2):165–179, February 2014. URL: http://dx.doi.org/10.2217/imt.13.165, doi:10.2217/imt.13.165. This article has 35 citations and is from a peer-reviewed journal.](https://doi.org/10.2217/imt.13.165)

[5. (Gjerstorff2006Identification) Morten Gjerstorff, Vivian Benoit, Anne-Vibeke Laenkholm, Ole Nielsen, Lene Johansen, and Henrik Ditzel. Identification of genes with altered expression in medullary breast cancer vs. ductal breast cancer and normal breast epithelia. International Journal of Oncology, June 2006. URL: http://dx.doi.org/10.3892/ijo.28.6.1327, doi:10.3892/ijo.28.6.1327. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/ijo.28.6.1327)